Modalis Therapeutics Corporation’s after-hours PTS price rose to ¥35.5, up ¥0.5 from the TSE closing price. In its financial results for the six months ended June 2026, business revenue remained at zero, while the operating loss was approximately ¥1.0 billion and the interim net loss was approximately ¥92 million. The company secured a cash balance of approximately ¥3.02 billion. The earnings announcement was made on 10 August 2026.
Modalis Therapeutics Corporation’s after-hours PTS price is currently ¥35.5. As of 23:46, the after-hours trading price was ¥35.5, up ¥0.5, or 1.43%, from the previous day’s closing price. After-hours trading prices are displayed based on J-Market information from Japan Next Securities, with the trading price and change from the TSE closing price shown together.
According to a summary of the latest earnings report, business revenue remained at zero for the six months ended June 2026. The operating loss was approximately ¥1.0 billion, and the interim net loss was approximately ¥92 million. Financing activities secured a cash balance of approximately ¥3.02 billion, and the company stated that there was no uncertainty regarding its ability to continue as a going concern.
The latest earnings announcement was made on 10 August 2026. Key points to watch in future results include progress in preparing MDL-101 for clinical development and validation results from subsequent pipeline programs, while the continued high level of research and development expenses and the timing and terms of financing remain important factors.